癌症研究
前列腺癌
免疫疗法
基因敲除
CD8型
医学
CX3CL1型
癌症免疫疗法
流式细胞术
CCL22型
癌症
基因签名
趋化因子
肿瘤浸润淋巴细胞
生物
T细胞
转录组
免疫系统
细胞培养
人性化鼠标
免疫学
癌细胞
细胞因子
人源化抗体
DU145型
肿瘤微环境
细胞毒性T细胞
作者
Jie Yang,Chuan Zhou,Wenbo Zhang,Han He,Jia Wang,Chao Wang,Fenghai Zhou
出处
期刊:
[Wiley]
日期:2026-09-22
摘要
Prostate cancer (PCa) is typically immunologically ‘cold’, which limits the effectiveness of immunotherapy, and this study sought to identify key genes driving this immunosuppressive phenotype and assess their therapeutic potential. We analyzed transcriptomic data from 487 TCGA‐PRAD patients and three Gene Expression Omnibus datasets; weighted gene co‐expression network analysis was used to identify cancer‐related genes, TIMER to evaluate their influence on the tumor microenvironment, and findings were validated via flow cytometry on 32 clinical PCa specimens. Immunoblotting measured Nrf2, p‐AKT, and p‐GSK‐3β levels, while ChIP‐qPCR assessed Nrf2 and RNA polymerase II binding to the CX3CL1 promoter, and functional studies were conducted in allograft and xenograft mouse models using GapmeR antisense oligonucleotides combined with anti‐PD‐1 antibodies or PSMA‐targeted CAR‐T cells. We found PPP1R14B (PP1 regulatory inhibitor subunit 14B) was overexpressed in PCa and associated with poor prognosis, promoting PCa cell proliferation, suppressing apoptosis, and correlating with increased tumor purity but reduced CD8 + T‐cell infiltration; mechanistically, CX3CL1 was regulated by Nrf2 and PPP1R14B elevated p‐AKT/p‐GSK‐3β to stabilize Nrf2, which bound the CX3CL1 promoter, suppressed its expression, and impaired CD8 + T‐cell chemotaxis. GapmeR‐mediated PPP1R14B knockdown suppressed tumor growth and enhanced anti‐PD‐1/CAR‐T efficacy in mice, indicating PPP1R14B is a promising target to overcome PCa immunotherapy resistance. © 2026 The Pathological Society of Great Britain and Ireland.
科研通智能强力驱动
Strongly Powered by AbleSci AI